Why the study?
Do plasma MR-proADM and CT-proET-1 levels predict mortality in outpatients with chronic heart failure?
Do plasma MR-proADM and CT-proET-1 levels predict mortality in outpatients with chronic heart failure?
MR-proADM is an important prognostic marker for mortality in outpatients with chronic heart failure, particularly those with mild to moderate symptoms.
No takes yet. Share an insight, caveat, or question.
MR-proADM may aid mortality risk stratification in chronic HF outpatients; hypothesis-generating pending prospective validation.
Adlbrecht et al. (2009) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: